• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4643608)   Today's Articles (5)   Subscriber (50558)
For: ten Holte P, Van Emelen K, Janicot M, Fong PC, de Bono JS, Arts J. HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. In: Bradbury RH, editor. Cancer. Berlin: Springer Berlin Heidelberg; 2007. pp. 293-331. [DOI: 10.1007/7355_2006_007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Number Cited by Other Article(s)
1
Debata PR, Castellanos MR, Fata JE, Baggett S, Rajupet S, Szerszen A, Begum S, Mata A, Murty VV, Opitz LM, Banerjee P. A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells. Gynecol Oncol 2012;129:145-53. [PMID: 23234806 DOI: 10.1016/j.ygyno.2012.12.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Revised: 11/29/2012] [Accepted: 12/03/2012] [Indexed: 11/29/2022]
2
Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2011;21:324-8. [DOI: 10.1016/j.bmcl.2010.11.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2010] [Revised: 10/29/2010] [Accepted: 11/01/2010] [Indexed: 01/03/2023]
3
Raeppel S, Zhou N, Gaudette F, Leit S, Paquin I, Larouche G, Moradei O, Fréchette S, Isakovic L, Delorme D, Fournel M, Kalita A, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Rahil J, Wang J, Besterman JM, Murakami K, Li Z, Vaisburg A. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103). Bioorg Med Chem Lett 2009;19:644-9. [DOI: 10.1016/j.bmcl.2008.12.048] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2008] [Revised: 12/11/2008] [Accepted: 12/12/2008] [Indexed: 11/28/2022]
4
Wahhab A, Smil D, Ajamian A, Allan M, Chantigny Y, Therrien E, Nguyen N, Manku S, Leit S, Rahil J, Petschner AJ, Lu AH, Nicolescu A, Lefebvre S, Montcalm S, Fournel M, Yan TP, Li Z, Besterman JM, Déziel R. Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett 2009;19:336-40. [DOI: 10.1016/j.bmcl.2008.11.081] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2008] [Revised: 11/20/2008] [Accepted: 11/21/2008] [Indexed: 11/24/2022]
5
4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett 2008;18:1502-6. [DOI: 10.1016/j.bmcl.2007.12.057] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2007] [Revised: 12/18/2007] [Accepted: 12/21/2007] [Indexed: 11/18/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA